Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Common Equity: 2019-2025

Historic Common Equity for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $369.0 million.

  • 4D Molecular Therapeutics' Common Equity fell 33.27% to $369.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $369.0 million, marking a year-over-year decrease of 33.27%. This contributed to the annual value of $510.6 million for FY2024, which is 65.87% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Common Equity of $369.0 million as of Q3 2025, which was down 12.33% from $420.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Common Equity's 5-year high stood at $600.6 million during Q1 2024, with a 5-year trough of $218.6 million in Q1 2023.
  • Over the past 3 years, 4D Molecular Therapeutics' median Common Equity value was $420.9 million (recorded in 2025), while the average stood at $426.7 million.
  • In the last 5 years, 4D Molecular Therapeutics' Common Equity skyrocketed by 174.72% in 2024 and then crashed by 33.27% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Common Equity (Quarterly) stood at $319.1 million in 2021, then declined by 27.50% to $231.3 million in 2022, then skyrocketed by 33.07% to $307.8 million in 2023, then soared by 65.87% to $510.6 million in 2024, then plummeted by 33.27% to $369.0 million in 2025.
  • Its last three reported values are $369.0 million in Q3 2025, $420.9 million for Q2 2025, and $469.7 million during Q1 2025.